logo

Intra-Cellular Therapies, Inc. (ITCI)



Trade ITCI now with
  Date
  Headline
5/3/2018 7:22:23 AM Intra-Cellular Therapies Q1 Net Loss $35.5 Mln Or $0.65/Shr Vs Loss Of $26.9 Mln Or $0.62/Shr Last Year
3/13/2018 7:36:27 AM Intra-Cellular Therapies Announces Positive Pre-NDA Meeting With FDA For Lumateperone For Schizophrenia
3/1/2018 7:21:58 AM Intra-Cellular Therapies Q4 Net Loss $30.2 Mln Or $0.56/Shr Vs Net Loss Of $27.5 Mln Or $0.64/Shr Last Year
2/8/2018 6:14:21 AM RBC Capital Markets Starts Intra-Cellular Therapies, Inc. (ITCI) At Outperform With $33 Price Target
12/7/2017 8:05:45 AM Intra-Cellular Therapies Presents Data On Lumateperone, ITI-214 And ITI-333
11/20/2017 7:03:02 AM Intra-Cellular Therapies Gets FDA Fast Track Designation For Lumateperone For Treatment Of Schizophrenia
11/14/2017 8:10:11 AM Intra-Cellular Therapies Presents Data On Mechanism Of Action Of Lumateperone And ITI-214
11/8/2017 7:33:56 AM Intra-Cellular Therapies Q3 Net Loss $22.9 Mln Or $0.53/shr Vs Loss Of $30.3 Mln Or $0.70/shr Last Year
10/3/2017 8:04:45 AM Intra-Cellular Therapies Begins Enrollment Of Clinical Trial Evaluating ITI-214 In Patients With Parkinson’s Disease
9/27/2017 10:48:19 PM Intra-Cellular Therapies Prices Offering Of 9.68 Mln Shares At $15.50/shr
9/26/2017 4:04:48 PM Intra-Cellular Therapies Announces Proposed Public Offering Of Common Stock
9/7/2017 7:22:53 AM Intra-Cellular Therapies Announces Positive Topline Data From Open-label Safety Switching Study With Lumateperone